B-lymphocyte antigen CD20 — Drug Target

All drugs that target B-lymphocyte antigen CD20 — marketed and clinical-stage. Includes 4 drug classes acting on this target.

Drug classes

CD20-directed Cytolytic Antibody [EPC] · CD20-directed Cytolytic Antibody · Bispecific CD20-directed CD3 T Cell Engager [EPC] · CD20-directed Radiotherapeutic Antibody

Marketed (10)

• Ocrevus · Roche · CD20-directed Cytolytic Antibody [EPC] · Neuroscience
  Ocrevus works by binding to the CD20 protein on B cells, marking them for destruction and reducing their ability to contribute to the disease process.
• Mabthera · Roche · CD20-directed Cytolytic Antibody · Oncology
• Gazyva · Roche · CD20-directed Cytolytic Antibody [EPC] · Oncology
  Gazyva binds to the CD20 antigen on B-lymphocytes, triggering their destruction.
• Columvi · Roche · Bispecific CD20-directed CD3 T Cell Engager [EPC] · Oncology
  Columvi works by binding to the CD20 protein on B-cell lymphoma cells, triggering an immune response to destroy the cancer cells.
• Arzerra · GlaxoSmithKline · Oncology
• LUNSUMIO · GENENTECH INC · Oncology
• Ocrevus · Kessler Foundation · Neuroscience
• BRIUMVI · TG THERAPEUTICS, INC · CD20-directed Cytolytic Antibody [EPC] · Neuroscience
• Lunsumio · Roche · Oncology
  Lunsumio works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.
• Mabthera · Roche · CD20-directed Cytolytic Antibody [EPC] · Oncology
  Mabthera works by binding to the CD20 antigen on B-lymphocytes, triggering their destruction.

Phase 1 pipeline (1)

• Gazyvaro · Incyte Corporation · Oncology